Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Christensen

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Biological Psychiatry|January 28, 2004
Neuroimaging correlates of anxiety after pediatric traumatic brain injuryRoma A Vasa, Marco Grados, Beth Slomine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitorKai Wang, Qin Zhang, Danan Li, et al.
Molecular & Cellular Proteomics : MCP|August 18, 2010
Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cellsTiannan Guo, Yi Zhu, Chee Sian Gan, et al.
Resuscitation|December 21, 2018
Pediatric out-of-hospital cardiac arrest: Time to goal target temperature and outcomesFrank W Moler, Faye S Silverstein, Vinay M Nadkarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Comparative Medicine|December 12, 2013
Contrast agents for quantitative microCT of lung tumors in miceKush Lalwani, Anand Giddabasappa, Danan Li, et al.
Journal of Medicinal Chemistry|August 16, 2013
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in ratsJ Jean Cui, Hong Shen, Michelle Tran-Dubé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibitionYing Zhang, Kaitlyn E Farenholtz, Yanzhi Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionMark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
JCO Precision Oncology|February 9, 2022
Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case SeriesMiriam T Jacobs, Nisha A Mohindra, Lindsey Shantzer, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Biological Psychiatry|January 28, 2004
Neuroimaging correlates of anxiety after pediatric traumatic brain injuryRoma A Vasa, Marco Grados, Beth Slomine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitorKai Wang, Qin Zhang, Danan Li, et al.
Molecular & Cellular Proteomics : MCP|August 18, 2010
Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cellsTiannan Guo, Yi Zhu, Chee Sian Gan, et al.
Resuscitation|December 21, 2018
Pediatric out-of-hospital cardiac arrest: Time to goal target temperature and outcomesFrank W Moler, Faye S Silverstein, Vinay M Nadkarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Comparative Medicine|December 12, 2013
Contrast agents for quantitative microCT of lung tumors in miceKush Lalwani, Anand Giddabasappa, Danan Li, et al.
Journal of Medicinal Chemistry|August 16, 2013
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in ratsJ Jean Cui, Hong Shen, Michelle Tran-Dubé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibitionYing Zhang, Kaitlyn E Farenholtz, Yanzhi Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionMark M Awad, Geoffrey R Oxnard, David M Jackman, et al.
JCO Precision Oncology|February 9, 2022
Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case SeriesMiriam T Jacobs, Nisha A Mohindra, Lindsey Shantzer, et al.
Pageof 5